Skip to main content
XNCR logo

XNCR · Xencor Inc · Documents

Track XNCR — free
$35.40 -1.69 (-4.56%) At close · Nov 16 Q4 2023 earnings call transcript
Market Cap
$2.66B
Shares
75.04M
Volume · Nov 16 1.03M Avg daily vol (3M) 1.55M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $125.58M up 13.7% 10-K filed Feb 25, 2026 Quarterly report FY2026 Q3 Revenue $116.52M up 454.9% 10-Q filed Nov 4, 2026 Latest results Third-quarter revenue $116.5 million, net income $39.4 million 8-K filed Nov 4, 2026 Earnings call Q4 2023 earnings call Held Feb 27, 2024
2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
XmAb819 delivered 45.5% confirmed response rate

XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties.

Revenue $116.52M ▲ 454.9% Net income $39.44M Diluted EPS $0.50
Read from the MD&A section
4 source passages
XmAb819 (ENPP3 x CD3): As of the October 1, 2026 data-cut, the efficacy-evaluable cohort at the 400 mcg/kg intravenous (IV) dose (n=11) reported five confirmed partial responses for a confirmed objective response rate of 45.5% per investigator assessment (RECIST v1.1), with one unconfirmed partial response for an unconfirmed objective response rate of 55%. Pursuant to the Settlement Agreement, we are entitled to receive aggregate consideration of $105.0 million from Alexion, payable in two equal installments of $52.5 million. Following the settlement, Alexion has no further obligation to pay royalties on U.S. sales of Ultomiris. Open the document at this passage
Nov 4
Current report 8-K
Third-quarter revenue $116.5 million, net income $39.4 million

Xencor reported third-quarter revenue of $116.5 million and net income of $39.4 million, versus $21.0 million revenue and a $6.0 million net loss in 2025. It held $555.7 million in cash, cash equivalents and marketable debt securities.

Financial results
3 source passages
Revenue for the third quarter ended September 30, 2026 was $116.5 million, compared to $21.0 million for the same period in 2025. Net income attributable to Xencor for the third quarter ended September 30, 2026 was $39.4 million, or $0.50 on a fully diluted per share basis, compared to a net loss of $6.0 million, or $(0.08) on a fully diluted per share basis, for the same period in 2025. Cash, cash equivalents and marketable debt securities totaled $555.7 million as of September 30, 2026, compared to $610.8 million as of December 31, 2025. Open the document at this passage
Oct 26
Current report 8-K Events of Oct 25
Financial results, Regulation FD disclosure, Other events

Xencor selected 400 mcg/kg for XmAb819 as the proposed intravenous RP3D after reporting 45.5% cORR, 55% uORR and an 82% 6-month PFS Kaplan-Meier estimate. It plans to discuss a potential accelerated approval pathway with the FDA in 1H2027.

Read from the first part of this long document
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $51.22M ▲ 17.5% Net loss $21.73M Diluted EPS -$0.29
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $4.52M ▼ 86.2% Net loss $128.92M Diluted EPS -$1.71
Feb 25
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $125.58M ▲ 13.7% Net loss $91.92M Diluted EPS -$1.24
2025
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $110.49M ▼ 36.7% Net loss $232.62M Diluted EPS -$3.58
Feb 24
Annual report 10-K/A FY2023, ended Dec 31
Annual report for FY2023
Revenue $174.62M ▲ 6.1% Net loss $133.13M Diluted EPS -$2.20
2024
Showing 1–50 of 142 documents
Key facts CIK 1326732 CUSIP 98401F105 13F (30d) 205 filings 189 filers Visit website Investor relations